US protection ending in 2030
As of the edition of 20 October 2026, 56 drugs have US protection that ends in 2030; 38 of them have at least one company on route B because of it.
Sources: FDA Orange Book and Purple Book, other approval registers.
56 drugs
| Drug | US protection | Status | Holder | Target | Route B rows |
|---|---|---|---|---|---|
| Aceclidine | Ends 2030 (exclusivity) | Marketed | LENZ Therapeutics | 0 | |
| Acoltremon | Ends 2030 (exclusivity) | Marketed | Alcon | TRPM8 | 1 |
| Aflibercept | Ends 2030 (orphan exclusivity) | Marketed | Regeneron | PGF, VEGFA | 4 |
| Andexanet alfa | Ends 2030 (computed from the first US licence) | Marketed | AstraZeneca | TFPI | 0 |
| Aripiprazole lauroxil | Ends 2030 (patent) | Marketed | Alkermes | DRD2, HTR1A, HTR2A | 3 |
| Atrasentan | Ends 2030 (exclusivity) | Marketed | Novartis | EDNRA | 1 |
| Axitinib | Ends 2030 (patent) | Marketed | Pfizer | FLT1, FLT4, KDR | 0 |
| Birch triterpenes | Ends 2030 (exclusivity) | Marketed | Chiesi Farmaceutici | 0 | |
| Burosumab | Ends 2030 (computed from the first US licence) | Marketed | Kyowa Kirin | FGF23 | 1 |
| Calaspargase pegol | Ends 2030 (computed from the first US licence) | Marketed | Servier | 0 | |
| Casimersen | Ends 2030 (patent) | Marketed | Avi Biopharma | DMD | 0 |
| Cemiplimab | Ends 2030 (computed from the first US licence) | Marketed | Regeneron | PDCD1 | 2 |
| Cenegermin | Ends 2030 (computed from the first US licence) | Marketed | Dompé Farmaceutici | NTRK1, NTRK2, NTRK3 | 3 |
| Coagulation factor x human | Ends 2030 (orphan exclusivity) | Marketed | Bio Products Laboratory Limited | 0 | |
| Dabrafenib | Ends 2030 (patent) | Marketed | Novartis | BRAF | 1 |
| Damoctocog alfa pegol | Ends 2030 (computed from the first US licence) | Marketed | Bayer | 0 | |
| Doxecitine | Ends 2030 (exclusivity) | Marketed | UCB | 0 | |
| Elapegademase | Ends 2030 (computed from the first US licence) | Marketed | Chiesi | 0 | |
| Eliglustat | Ends 2030 (patent) | Marketed | Sanofi | UGCG | 1 |
| Elinzanetant | Ends 2030 (exclusivity) | Marketed | Bayer | TACR1, TACR3 | 2 |
| Emapalumab | Ends 2030 (computed from the first US licence) | Marketed | Swedish Orphan Biovitrum | IFNG | 1 |
| Encorafenib | Ends 2030 (exclusivity) | Marketed | Pfizer | BRAF | 3 |
| Erenumab | Ends 2030 (computed from the first US licence) | Marketed | Amgen | CALCRL | 1 |
| Etripamil | Ends 2030 (exclusivity) | Marketed | Milestone Pharmaceuticals | CACNA1C | 1 |
| Fremanezumab | Ends 2030 (computed from the first US licence) | Marketed | Teva | CALCA, CALCB | 4 |
| Galcanezumab | Ends 2030 (computed from the first US licence) | Marketed | Eli Lilly | CALCA, CALCB | 2 |
| Ibalizumab | Ends 2030 (computed from the first US licence) | Marketed | Theratechnologies | CD4 | 0 |
| Lanadelumab | Ends 2030 (computed from the first US licence) | Marketed | Takeda | KLKB1 | 1 |
| Lifitegrast | Ends 2030 (patent) | Marketed | Bausch Health | ITGAL | 1 |
| Lotilaner | Ends 2030 (patent) | Marketed | Tarsus Pharmaceuticals | 0 | |
| Lusutrombopag | Ends 2030 (patent) | Marketed | Shionogi | MPL | 1 |
| Macimorelin | Ends 2030 (exclusivity) | Marketed | COSCIENS Biopharma | GHSR | 2 |
| Mogamulizumab | Ends 2030 (computed from the first US licence) | Marketed | Kyowa Kirin | CCR4 | 1 |
| Motixafortide acetate | Ends 2030 (exclusivity) | Marketed | Ayrmid Pharma | CXCR4 | 1 |
| Moxetumomab pasudotox | Ends 2030 (computed from the first US licence) | Marketed | AstraZeneca | CD22, EEF2 | 2 |
| Neratinib | Ends 2030 (patent) | Marketed | Puma Biotechnology | EGFR | 2 |
| Nusinersen | Ends 2030 (patent) | Marketed | Biogen | SMN2 | 1 |
| Omadacycline | Ends 2030 (patent) | Marketed | Transcept Pharmaceuticals | 0 | |
| Pacritinib | Ends 2030 (patent) | Marketed | Swedish Orphan Biovitrum | FLT3, JAK2 | 2 |
| Palovarotene | Ends 2030 (exclusivity) | Marketed | Ipsen | RARG | 1 |
| Patiromer sorbitex calcium | Ends 2030 (patent) | Marketed | Sanofi | 0 | |
| Pegvaliase | Ends 2030 (computed from the first US licence) | Marketed | Amicus Therapeutics | 0 | |
| Pimavanserin | Ends 2030 (patent) | Marketed | Acadia Pharmaceuticals | HTR2A | 1 |
| Quizartinib | Ends 2030 (exclusivity) | Marketed | Daiichi Sankyo | CSF1R, FLT3, KIT | 3 |
| Raltegravir | Ends 2030 (patent) | Marketed | Merck & Co. | 0 | |
| Ravulizumab | Ends 2030 (computed from the first US licence) | Marketed | AstraZeneca | C5 | 0 |
| Selexipag | Ends 2030 (patent) | Marketed | Johnson & Johnson | PTGIR | 1 |
| Sildenafil | Ends 2030 (exclusivity) | Marketed | Viatris | PDE5A | 3 |
| Sotagliflozin | Ends 2030 (patent) | Marketed | Lexicon Pharmaceuticals | SLC5A2 | 2 |
| Tagraxofusp | Ends 2030 (computed from the first US licence) | Marketed | Stemline Therapeutics | EEF2, IL3RA | 4 |
| Tedizolid phosphate | Ends 2030 (patent) | Marketed | Merck & Co. | 0 | |
| Tepotinib | Ends 2030 (patent) | Marketed | Merck KGaA | MET | 1 |
| Tildrakizumab | Ends 2030 (computed from the first US licence) | Marketed | SUN Pharmaceutical Industries | IL23A | 1 |
| Tradipitant | Ends 2030 (exclusivity) | Marketed | Vanda Pharmaceuticals | TACR1 | 1 |
| Trametinib | Ends 2030 (patent) | Marketed | Novartis | MAP2K1, MAP2K2 | 2 |
| Vemurafenib | Ends 2030 (patent) | Marketed | Roche | BRAF | 1 |
Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.
Which companies are on route B in 2030
In the product38 of these 56 drugs have at least one company on route B. Which companies, and their scores, are in the product.
Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.